Data gathered: November 23
AI Stock Analysis - Regeneron (REGN)
Analysis generated October 14, 2024. Powered by Chat GPT.
Regeneron Pharmaceuticals, Inc. is a biotechnology company that invents life-transforming medicines for people with serious diseases. Founded in 1988 and headquartered in Tarrytown, New York, Regeneron employs a research-driven approach to drug discovery and development. Leveraging its proprietary VelociSuite® technologies, the company has advanced numerous FDA-approved treatments that address a broad spectrum of ailments, including ophthalmology, oncology, immunology, cardiovascular, and infectious diseases.
Stock Alerts - Regeneron (REGN)
 |
Regeneron | November 15 Greg Landsman (member of U.S. congress) is selling shares |
|
Regeneron | November 13 Web Traffic is up by 53.9% over the last month. |
|
Regeneron | November 7 Josh Gottheimer (member of U.S. congress) is selling shares |
|
Regeneron | October 31 Price is down by -7.9% in the last 24h. |
Alternative Data for Regeneron
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 673 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 417,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 70 | Sign up | Sign up | Sign up |
| Patents | 1,391 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 779 | Sign up | Sign up | Sign up |
| Facebook Followers | 17,972 | Sign up | Sign up | Sign up |
| Instagram Followers | 13,513 | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 48 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 15,913 | Sign up | Sign up | Sign up |
| Twitter Followers | 33,111 | Sign up | Sign up | Sign up |
| Twitter Mentions | 15 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 58 | Sign up | Sign up | Sign up |
| Lobbying Cost | $133,000 | Sign up | Sign up | Sign up |
| Business Outlook | 80 | Sign up | Sign up | Sign up |
| Linkedin Employees | 15,392 | Sign up | Sign up | Sign up |
About Regeneron
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
| Price | $738.00 |
| Target Price | Sign up |
| Volume | 1,030,000 |
| Market Cap | $81.8B |
| Year Range | $738 - $1201.76 |
| Dividend Yield | 0% |
| PE Ratio | 18.41 |
| Analyst Rating | 74% buy |
| Industry | Biotechnology |
In the news
 |
Caprock Group LLC Cuts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)November 21 - ETF Daily News |
 |
Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right NowNovember 19 - Yahoo |
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitorsNovember 19 - MarketWatch |
|
 |
Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)November 19 - SeekingAlpha |
 |
Regeneron: The Biotech Stock To Buy NowNovember 18 - SeekingAlpha |
 |
Wolfe Research Initiates Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN)November 18 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 3.72B | 714M | 3.01B | 1.34B | 0 | 12.460 |
| Q2 '24 | 3.55B | 759M | 2.79B | 1.43B | 1.21B | 11.560 |
| Q1 '24 | 3.13B | 689M | 2.44B | 722M | 873M | 9.550 |
| Q4 '23 | 3.42B | 947M | 2.47B | 1.16B | 1.26B | 11.860 |
| Q3 '23 | 3.34B | 641M | 2.7B | 1.01B | 1.11B | 11.590 |
Insider Transactions View All
| RYAN ARTHUR F filed to sell 17,678 shares at $1042.3. October 3 '24 |
| RYAN ARTHUR F filed to sell 17,582 shares at $1059.3. October 3 '24 |
| RYAN ARTHUR F filed to sell 17,586 shares at $1056.7. October 3 '24 |
| RYAN ARTHUR F filed to sell 17,592 shares at $1053.5. October 3 '24 |
| RYAN ARTHUR F filed to sell 17,673 shares at $1043.4. October 3 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Greg Landsman |
Nov 15, 24 | Sell | $1K - $15K |
| Josh Gottheimer |
Nov 7, 24 | Sell | $1K - $15K |
| Ro Khanna |
Oct 8, 24 | Buy | $1K - $15K |
Read more about Regeneron (REGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Regeneron?
The Market Cap of Regeneron is $81.8B.
What is Regeneron's PE Ratio?
As of today, Regeneron's PE (Price to Earnings) ratio is 18.41.
What is the current stock price of Regeneron?
Currently, the price of one share of Regeneron stock is $738.00.
How can I analyze the REGN stock price chart for investment decisions?
The REGN stock price chart above provides a comprehensive visual representation of Regeneron's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Regeneron shares. Our platform offers an up-to-date REGN stock price chart, along with technical data analysis and alternative data insights.
Does REGN offer dividends to its shareholders?
As of our latest update, Regeneron (REGN) does not offer dividends to its shareholders. Investors interested in Regeneron should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Regeneron?
Some of the similar stocks of Regeneron are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.